
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is positioned favorably within the growing metabolic therapeutics market, as evidenced by a staggering 587% increase in GLP-1 drug prescriptions from 2019 to 2024, indicating a rising acknowledgment of effective treatments for obesity and type 2 diabetes. The company's innovative approach, exemplified by the anticipated advancements in its first-in-human Phase 1 trial and scalable manufacturing capabilities, suggests a promising pathway toward significant market penetration, with updated models projecting a peak penetration of Revita to 2%. Furthermore, the positive REMAIN-1 trial data highlights the potential of GLP-1 PGTx not only to improve blood glucose and weight control compared to existing therapies but also to provide benefits in lipid profiles and cardiovascular risk factors, underscoring its strategic advantage in addressing multiple facets of metabolic disease.
Bears say
Fractyl Health faces significant challenges regarding its financial outlook, primarily due to a high cash burn rate associated with its development and commercial programs, which may not be adequately offset by potential milestone revenue payments. Additionally, the gradual loss of β-cell function in type 2 diabetes patients raises concerns about the long-term efficacy of Fractyl's therapeutic interventions, particularly related to insulin production and control of hyperglycemia. The potential inability to secure sufficient capital to advance its Revita and Rejuva platforms further contributes to a negative outlook on the company’s financial stability and growth prospects.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares